Pyxis Oncology (PYXS) Expected to Announce Earnings on Tuesday

Pyxis Oncology (NASDAQ:PYXS) will likely be announcing its Q4 2025 results before the market opens on Tuesday, March 17th. Analysts expect the company to announce earnings of ($0.35) per share for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, March 20, 2026 at 12:30 PM ET.

Pyxis Oncology Stock Up 0.7%

Pyxis Oncology stock opened at $1.54 on Friday. The firm has a market capitalization of $95.88 million, a PE ratio of -0.96 and a beta of 1.45. Pyxis Oncology has a 52 week low of $0.83 and a 52 week high of $5.55. The firm’s 50-day simple moving average is $1.53 and its 200 day simple moving average is $2.50.

Analysts Set New Price Targets

A number of equities analysts have issued reports on PYXS shares. HC Wainwright lifted their target price on shares of Pyxis Oncology from $5.00 to $7.00 and gave the stock a “buy” rating in a research report on Friday, December 19th. Stephens increased their price target on shares of Pyxis Oncology from $5.00 to $8.00 and gave the company an “overweight” rating in a research report on Monday, November 24th. Royal Bank Of Canada dropped their price objective on shares of Pyxis Oncology from $8.00 to $5.00 and set an “outperform” rating for the company in a research note on Thursday, December 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Pyxis Oncology in a research report on Thursday, January 22nd. Finally, Wall Street Zen lowered Pyxis Oncology from a “hold” rating to a “sell” rating in a research note on Sunday. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Pyxis Oncology presently has a consensus rating of “Moderate Buy” and an average target price of $7.20.

Institutional Investors Weigh In On Pyxis Oncology

Several hedge funds have recently modified their holdings of the company. XTX Topco Ltd grew its holdings in shares of Pyxis Oncology by 1,533.0% during the fourth quarter. XTX Topco Ltd now owns 289,033 shares of the company’s stock worth $332,000 after buying an additional 271,334 shares in the last quarter. Toronto Dominion Bank purchased a new position in shares of Pyxis Oncology during the fourth quarter valued at approximately $86,000. Quadrature Capital Ltd purchased a new position in shares of Pyxis Oncology during the fourth quarter valued at approximately $116,000. Maia Wealth LLC acquired a new stake in Pyxis Oncology during the fourth quarter worth approximately $25,000. Finally, Engineers Gate Manager LP acquired a new stake in Pyxis Oncology during the fourth quarter worth approximately $26,000. 39.09% of the stock is owned by institutional investors and hedge funds.

About Pyxis Oncology

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.